| Biomarker ID | 234 |
| PMID | 17460773 |
| Year | 2007 |
| Biomarker | Metaclassifier: ENC1+GJB1+MYO6+AMACR+TSPAN13+PRKCBP+C20ORF74+DAPK1+IMAGE:396839 + ENC1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (AMACR): Lipid and lipoprotein metabolism, T cell receptor regulation of apoptosis, Metabolism, Peroxisome, Beta-oxidation of pristanoyl-CoA |
| Experiment | Benign Prostate Vs Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Total of 56 patients were selected from Stanford Data set and were used for training. Rest of the samples from Stanford Data set, University of Michigan, University of Pittsburg were treated as validation sets. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.96 (Stanford); 0.99 (UM); 0.99 (Pittsburg) |
| Accuracy | NA |
| Level Of Significance | p<0.0005 |
| Method Used | NA |
| Clinical | No |
| Remarks | Results on Stanford Data Set (Validation Set). Metaclassifier is defined as: combining multiple classifiers in general yields better prediction performance, as it involves more genes and multiple predictive signatures. Thus, we composed a metaclassifier based on the above five classifiers. For each sample, the calculated prediction scores of the five classifiers were totaled to an overall prediction score, which was then defined as the prediction score of the metaclassifier for that sample |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | ENC1, GJB1, MYO6, AMACR, TSPAN13, ZMYND8, RALGAPA2, DAPK1, IMAGE:396839, ENC1 |